Wednesday, June 10, 2026

pharma Β· Breast Cancer Β· Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

HOFFMANN-LA ROCHE clinical programs β€” 15 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Intelligence Β· Clinical Programs

HOFFMANN-LA ROCHE projects

15 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 15 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Atezolizumab

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    approved small molecule completed

    1 trial
  2. BN44620

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial
  3. BN44621

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial
  4. Ganciclovir

    Hoffmann-La Roche

    Cytomegalovirus Infections

    approved small molecule completed

    1 trial
  5. Hemlibra 150 mg/mL solution for injection

    Hoffmann-La Roche

    Severe or Moderate Hemophilia A

    approved small molecule active

    1 trial
  6. Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]

    approved small molecule active

    1 trial
  7. PEG-IFN alfa-2a

    Hoffmann-La Roche

    Hepatitis C, Chronic

    approved small molecule completed

    1 trial
  8. Satralizumab 120 mg

    Hoffmann-La Roche

    Neuromyelitis Optica Spectrum Disorder

    approved small molecule terminated

    1 trial
  9. Vabysmo 120 mg/mL solution for injection

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration

    approved small molecule active

    1 trial
  10. Vemurafenib

    Hoffmann-La Roche

    Neoplasms

    approved small molecule completed

    1 trial
  11. docetaxel

    Hoffmann-La Roche

    Breast Cancer

    approved small molecule completed

    2 trials
  12. epoetin beta [NeoRecormon]

    Hoffmann-La Roche

    Anemia

    approved small molecule terminated

    1 trial
  13. ibandronate [Bonviva/Boniva]

    Hoffmann-La Roche

    Post Menopausal Osteoporosis

    approved small molecule completed

    1 trial
  14. methoxy polyethylene glycol-epoetin beta [Mircera]

    Hoffmann-La Roche

    Anemia

    approved small molecule terminated

    2 trials
  15. trastuzumab [Herceptin]

    Hoffmann-La Roche

    Gastric Cancer

    approved small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

15 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.